Bascom Palmer Eye Institute Added as Site for Stem Cell Clinical Trial for Dry AMD
Advanced Cell Technology Inc., announced that the Bascom Palmer Eye Institute in Miami has received institutional review board approval as a site for the company’s phase 1/2 clinical trial for dry AMD using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
The phase 1/2 trial is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following subretinal transplantation into patients with dry AMD. The trial will enroll 12 patients, with cohorts of 3 patients each in an ascending dosage format.
Advanced Cell Technology will work with the team of Philip Rosenfeld, MD, a retina specialist and professor of ophthalmology at the University of Miami’s Miller School of Medicine. For more information about patient eligibility for the study, visit www.clinicaltrials.gov, identifier: NCT01344993.
TOP 5 ARTICLES FROM 2012
- Treatment of Retinal Vein Occlusion
Individualized therapy is crucial to good patient outcomes.
By Gaurav K. Shah, MD
- Intravitreal Aflibercept for AMD: 2-year Results
The VIEW 1 and 2 studies showed high degrees of safety and efficacy at 2 years.
By Jeffery S. Heier, MD
- Treatment of Vitreomacular Adhesion: Present Status, Future Prospects
The technology is already in use for diagnosis and management of some conditions.
By J. Sebag, MD, FACS, FRCOphth, FARVO
- Ocular Drug Delivery Systems for the Posterior Segment: A Review
By Noriyuki Kuno, PhD; and Shinobu Fujii
- A New Focus on the Vitreous and Its Role in Retinal Function
By Pravin U. Dugel, MD